Funding for this research was provided by:
Canadian Institutes of Health Research (CIHR OV2 – 170357)
Instituto de Salud Carlos III (CD018/0123, COV20/00110)
Gerencia Regional de Salud de Castilla y León (GRS COVID 53/A/20)
Received: 3 September 2020
Accepted: 18 November 2020
First Online: 14 December 2020
Ethics approval and consent to participate
: The study was approved by the Committee for Ethical Research of the coordinating institution, “Comite de Etica de la Investigacion con Medicamentos del Area de Salud de Salamanca”, code PI 2020 03 452. Informed consent was obtained orally when clinically possible. In the remaining cases, the informed consent waiver was authorized by the Ethics committee.
: Not applicable.
: The authors declare that they have no competing interests.